Clinical Trials Directory

Trials / Conditions / Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

7 registered clinical trials studyying Relapsed/Refractory B-cell Non-Hodgkin Lymphoma — 4 currently recruiting.

StatusTrialSponsorPhase
RecruitingA Phase I/IIa, Open-label, Single-center, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tol
NCT07376642
Suzhou Immunofoco Biotechnology Co., LtdEARLY_Phase 1
Not Yet RecruitingA Clinical Study to Explore CT1195E in Patients With Relapsed/Refractory B-Cell Neoplasms
NCT07234045
Institute of Hematology & Blood Diseases Hospital, ChinaPhase 1
RecruitingThe Safety, Tolerability, and Efficacy of IBR900 Cell Injection in Relapsed/Refractory B-cell Non Hodgkin Lymp
NCT07073833
Imbioray (Hangzhou) Biomedicine Co., Ltd.Phase 1
TerminatedA Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-
NCT06256484
Atara BiotherapeuticsPhase 1
Active Not RecruitingA Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin Lymphoma
NCT06561425
Galapagos NVPhase 1 / Phase 2
RecruitingTo Evaluate Safety and Efficacy of Autologous CD19 Chimeric Antigen Receptor (CAR)-T Cells in Relapsed/Refract
NCT06698484
National University of MalaysiaPhase 2
CompletedStudy Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Re
NCT02625480
Kite, A Gilead CompanyPhase 1 / Phase 2